Jie-Shan Meng

Targeting FDX1 with oridonin triggers cuproptosis and inhibits tumor progression in nasopharyngeal carcinoma.

Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with limited therapeutic options, highlighting the urgent need for novel anti-tumor agents. Oridonin, a bioactive diterpenoid derived from Isodon rubescens, has demonstrated broad-spectrum anticancer activities. However, its precise role in NPC remains largely...